Confirmation of menopause based on changes in follicle-stimulating hormone levels in patients who were administered dienogest

Hisayoshi Takagi, T. Sasagawa, Y Osaka
In: Clinical and Experimental Obstetrics & Gynecology · 2018 · vol. 45(2) , pp. 312–315 · doi:10.12891/ceog4029.2018 · W3036113552
article OA: bronze CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-07 ⓘ

This study found that increased follicle-stimulating hormone levels confirmed menopause in patients on dienogest, and the drug prevented endometriosis and adenomyosis recurrence.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Purpose of investigation: The appropriate time for patients to discontinue dienogest (DNG) after long-term use has been a recent topic of debate. Therefore, this study evaluated the timing for discontinuation of DNG in climacteric patients suffering from endometriosis and adenomyosis. Materials and Methods: DNG was orally administered at 2 mg/day for more than 12 months. The serum estradiol (E2) and follicle-stimulating hormone (FSH) levels were measured every three to six months. DNG was discontinued when the hormone levels changed to those characteristic of menopause. Results: FSH levels in three patients increased to more than 25.8 mIU/mL during DNG administration. They were thus diagnosed as having entered menopause. There was no recurrence of pain in these patients at one year after discontinuation of DNG. Conclusion: An increase in serum FSH levels could help in confirming the diagnosis of menopause. In addition, DNG prevented the recurrence of endometriosis and adenomyosis.
Full text 1,644 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Purpose of investigation: The appropriate time for patients to discontinue dienogest (DNG) after long-term use has been a recent topic of debate. Therefore, this study evaluated the timing for discontinuation of DNG in climacteric patients suffering from endometriosis and adenomyosis. Materials and Methods: DNG was orally administered at 2 mg/day for more than 12 months. The serum estradiol (E2) and follicle-stimulating hormone (FSH) levels were measured every three to six months. DNG was discontinued when the hormone levels changed to those characteristic of menopause. Results: FSH levels in three patients increased to more than 25.8 mIU/mL during DNG administration. They were thus diagnosed as having entered menopause. There was no recurrence of pain in these patients at one year after discontinuation of DNG. Conclusion: An increase in serum FSH levels could help in confirming the diagnosis of menopause. In addition, DNG prevented the recurrence of endometriosis and adenomyosis.

Keywords

- Dienogest - Endometriosis - Adenomyosis - Estradiol - Follicle-stimulating hormone

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisadenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (14)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK